hepatitis C drugs
-
FDA issues warning about hepatitis C drug as dozens of patients experience worsening liver function
The agency warned against use of AbbVie’s Mavyret, Gilead Sciences’ Vesovi and Merck’s Zepatier in patients with moderate to severe liver disease amid reports of 63 patients with liver decompensation, with some cases being fatal.
-
Drugmakers partner with England’s NHS in $1.3B hepatitis C push
NHS said it hopes to make England the first country to eliminate HCV. The effort will involve finding people living with the virus and providing drugs procured from AbbVie, Gilead and Merck.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
BioPharma, Payers, Pharma, Policy
Gilead to pay Merck $2.54B in largest-ever patent infringement case
A federal jury has awarded $2.54 billion in royalties to Merck, ruling against Gilead in a monumental patent infringement case involving two blockbuster hepatitis C drugs. The kicker? The judge has the power to triple that figure.
-
Morning Read: Pfizer marks milestone with construction of China biotech hub
Also, FDA launches Oncology Center of Excellence, Siemens has allocated more than $1 billion to its Next47 unit to work with startups with disruptive technology, Harvard Pilgrim Health Care is reimbursing for telemedicine through a deal with Doctor On Demand.
-
Morning Read: FDA greenlights Merck’s Hepatitis C drug aimed at lower price point
Also, Cambia Health Solutions is shutting down Wellero and HeartWare International nixed a deal to buy Valtech Cardio.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Boston Children’s enlists ResearchKit for hep C study
This study, called C Tracker, will give researchers insight into patients’ daily activity, monitor symptoms and assess the efficacy of treatments.
-
Here are some of the complexities of the drug cost debate
How is drug effectiveness determined? How do formulary designs, coverage decisions by PBMs, and third party reviews assess the efficacy and effectiveness of drugs?
-
There’s a life-saving hepatitis C drug (But you may not be able to afford it)
There’s a new drug regimen being touted as a potential cure for a dangerous liver virus […]